The 6 most recent market catalysts affecting $MLSS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 26, 2026
Corporate Catalyst
Neutral
Impact 65
Milestone Scientific Directors Convert $465K Loans Into Equity, Eliminating Debt And Achieving Debt‑Free Balance Sheet
Milestone Scientific's directors converted $465,000 of company debt into equity at a premium to the market price. This action immediately eliminates the company's outstanding note …
Aug 14, 2026
Corporate Catalyst
Bearish
Impact 85
Milestone Scientific shares are trading lower after the company reported Q2 financial results and issued Q3 sales guidance below analyst estimates.
This headline represents a significant corporate catalyst for Milestone Scientific (MLSS). The combination of missing Q2 analyst estimates and providing lower-than-expected Q3 guid…
Aug 14, 2026
Corporate Catalyst
Neutral
Impact 75
Conference Call:
Milestone Scientific Sees Q3 Sales $2.300M-$2.500M vs $2.510M Est
Milestone Scientific (MLSS) announced preliminary Q3 sales guidance ranging from $2.3 million to $2.5 million. This range is notably lower than the standing analyst estimate of $2.…
Aug 14, 2026
Corporate Catalyst
Neutral
Impact 75
Transcript: Milestone Scientific Q2 2026 Earnings Conference Call
Milestone Scientific (MLSS) announced a robust Q2 2026, with total revenue up 22% and its medical segment, driven by CompuFlo, surging 231%. This growth is supported by favorable M…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 75
Milestone Scientific Q2 EPS $(0.01), Inline, Sales $2.841M Beat $2.700M Estimate
Milestone Scientific's Q2 earnings report shows a mixed but generally positive picture. While EPS met expectations, the significant beat on sales (5.22% above consensus and a 22.30…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.